在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。本期特整理如下,供大家提前阅览。 研究简介 背景 AML在临床结局和疾病生物学...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。本期特整理如下,供大家提前阅览。 编者按:第66届美国血液学会(ASH)年会将于...
2017ELN:成人AML诊断与治疗推荐(治疗篇) 2010年欧洲白血病网(ELN)对成人AML(急性髓系白血病)的诊断与治疗首次做出推荐,得到认可,在临床实践中广泛应用,事隔7年AML的诊断与治疗有了大量进展,因此ELN对成人AML诊断与治疗推荐做出了更新。2017ELN:成人AML诊断与治疗推荐(诊断篇) ...
Models excluding results for ASXL1, CEBPA, RUNX1 and TP53, demonstrated that these mutations provide a limited overall contribution to risk stratification across the entire population, given the low frequency of mutations and confounding risk factors. Conclusions: While European LeukemiaNet guidelines ...
amlcg.final: an ExpressionSet that includes the normalized test set gene expression and phenotypic data after filtering to retain probe sets that mapped to transcripts included in the training set mixture cure model amlcg.frame: data.frame that includes the time-to-event outcome (cryr), censoring...
European LeukemiaNet (ELN) 2017 updated prognostic system for acute myeloid leukemia (AML), which incorporates both cytogenetic and molecular risks, stratifying patients into 3 distinct genetic risk groups: favorable, intermediate and adverse. While most patients in favorable risk group can be cured wi...
ELN2017 risk group ELN2017-IR vs ELN2017-FR .0003 1.838 1.321 2.557 Transplant, covariate time-dependent Transplant vs no transplant .0185 0.674 0.485 0.936 Discussion In the current analysis, we showed that, when implemented in the prospective, risk-adapted, MRD-driven, AML1310 GIMEMA protocol...
The ELN22 adverse (HR=3.05, 95% CI 1.18-7.87, p=0.014) and intermediate-risk (HR=1.57, 95% CI 0.85-2.92) groups had significantly inferior OS, compared to favorable risk. A high LSC burden at diagnosis predicted for PI MFC-MRD positive status (p=0.0013). LSC high AML had a ...